The Types segment classifies PCK1 antibodies by molecular architecture, each influencing production cost, performance consistency, and end‑user preference. Monoclonal antibodies dominate with an estimated 55 % share, as their single‑clone specificity enables reproducible epitope recognition across batches, essential for quantitative assays and regulatory submissions. Within this class, IgG1 and IgG2 subclasses are differentiated for Fc‑mediated functions, affecting signal‑amplification strategies. Polyclonal antibodies account for roughly 25 % of sales; they are generated from immunized animals and provide broader epitope coverage, which can be advantageous in exploratory studies but introduce variability that limits their use in diagnostic kits. Recombinant antibodies—including humanized, chimeric, and fully synthetic formats—represent an emerging 15 % slice, offering scalability and reduced animal dependency while maintaining high affinity; their engineered constant regions support customized detection platforms. The remaining 5 % consists of fragment formats such as Fab, scFv, and nanobodies, prized for tissue penetration and reduced steric hindrance in imaging applications. Collectively, these type categories constitute the market taxonomy for PCK1 Antibody segmentation and dictate pricing tiers across the sector.
